U.S. Markets open in 9 hrs 21 mins

Wilex AG (WL6.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
3.085-0.040 (-1.280%)
At close: 5:35PM CEST

Wilex AG

Grillparzerstrasse 18
Munich 81675
49 89 41 31 38 0

Full Time Employees50

Key Executives

Dr. Jan Schmidt-BrandChief Exec. Officer, Chief Financial Officer and Member of the Exec. Management Board301.28kN/A59
Prof. Andreas PahlChief Scientific Officer, Head of R&D and Member of the Exec. Mgmt Board210.68kN/AN/A
Sylvia WimmerMang. of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Wilex AG operates as a biopharmaceutical company that focuses on oncology and antibodies in Germany, rest of Europe, the United States, and internationally. Its product portfolio includes HDP-101, an antibody targeted amanitin conjugate (ATAC) candidate for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; CD19, an ATAC candidate for the treatment of haematological tumors; HuMAB 5B1, an ATAC candidate to treat metastatic pancreatic cancer; and NN, an ATAC candidate for treating leukemia. The company’s product portfolio also comprise RENCAREX, a Phase III clinical trial product candidate for the treatment of clear cell renal cell carcinoma; REDECTANE, which has completed a Phase III trial for the treatment of kidney cancer; and MESUPRON that has completed Phase IIa clinical trials for the treatment of pancreatic and breast cancers. Wilex AG also provides preclinical contract services. The company was formerly known as WILEX Biotechnology GmbH and changed its name to Wilex AG in February 2001. Wilex AG was founded in 1997 and is headquartered in Munich, Germany.

Corporate Governance

Wilex AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.